An open label, prospective, multicenter study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT595 as replacement therapy in patients with primary immunodeficiency disease (PID)

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2016
This article has no abstract
Epistemonikos ID: 0b71a65cfc4ed42750cda7f7fe3ea04c1162fa91
First added on: Jan 23, 2025